Adult Acute Myeloid Leukemia Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Adult Acute Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia+1 more
City of Hope Medical Center27 enrolled1 locationNCT05672147
Recruiting
Phase 1

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic Leukemia+1 more
University of Chicago30 enrolled1 locationNCT02333162
Recruiting
Phase 3

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Adult Acute Myeloid Leukemia
Priothera SAS366 enrolled108 locationsNCT05429632
Recruiting
Not Applicable

Novel Digital Application for Patients With Acute Leukemia

High-Risk Acute Myeloid LeukemiaPrimary Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia
Massachusetts General Hospital200 enrolled3 locationsNCT06472128
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 2

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

High Risk Myelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blastsde Novo Myelodysplastic Syndrome+7 more
M.D. Anderson Cancer Center270 enrolled1 locationNCT00801489
Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic127 enrolled2 locationsNCT03017820
Recruiting
Phase 1

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

Hematologic MalignancyAML (Acute Myelogenous Leukemia)Refractory Acute Myeloid Leukemia+3 more
Hangzhou Weben Pharma Co., Ltd18 enrolled1 locationNCT07014449
Recruiting

Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)

Adult Acute Myeloid Leukemia
University Hospital, Caen100 enrolled1 locationNCT06045819
Recruiting
Not Applicable

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Myelodysplastic SyndromeAdult Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid Leukemia
Ruijin Hospital78 enrolled1 locationNCT06329999